Leap Therapeutics And MacroGenics Among Early Winners And Losers At ESMO
Contrasting Market Reception For Rivals In GI Cancer
Two companies looking to challenge Merck’s Keytruda with new combinations have had contrasting reactions from investors
You may also be interested in...
Public Company Edition: Also, Roivant and two other biopharma firms close SPAC mergers and begin trading on the Nasdaq, Spero negotiated a royalty financing worth up to $125m and Phathom secured a $200m term loan.
Novartis has filed the PD-1 inhibitor tislelizumab, licensed from BeiGene, for second-line esophageal cancer with the FDA, the first submission outside China for the closely-watched therapy.
While the general lack of an overall survival benefit for MacroGenics’ drug in later-line breast cancer was not surprising, OS data were seen as important for commercial uptake of the drug.